Ivermectin & mild illness
The antiparasitic ivermectin does not seem to improve outcomes in mild COVID-19, according to a randomized, single-center trial in JAMA. Previous research has suggested a potential effect against SARS-CoV-2. In the new trial, roughly 400 adults in Colombia with mild COVID-19 who were within 7 days of symptom onset were randomized to receive ivermectin oral solution or placebo daily for 5 days. Patients could be at home or hospitalized without needing high-flow oxygen or mechanical ventilation. The primary outcome — time to resolution of symptoms — did not differ significantly between the groups (median: 10 days with ivermectin, 12 with placebo). By day 21, symptoms had resolved in roughly 80% of patients in each group. Some 7.5% of patients in the ivermectin group and 2.5% in the placebo group discontinued treatment because of adverse events.
Background: HIV and ID Observations post on ivermectin for COVID-19